Latest Healthcare News

Promisia Healthcare’s portfolio value jumps 17.1% to $107.2 million, driven by improved occupancy and operational efficiencies across all sites.

Unith Ltd (ASX:UNT) posted Q3 FY2026 revenue of A$1.26 million, secured a $2 million finance facility to fuel commercial expansion, and showcased significant advancements in its AI Digital Humans platform, including proprietary streaming technology and SDK launches.

Neuren Pharmaceuticals saw a 20% jump in Q1 2026 DAYBUE net sales to US$101 million, with royalties up 23%. The Japan trofinetide trial has been fast-tracked, and the new powder formulation DAYBUE STIX gains early traction.

Xenitra Limited has secured $1.25 million through a share placement to accelerate its OTC medicines rollout and expand its OPAL RWA token ecosystem, with shareholder approval pending for attached options.

Zip Co’s April update highlights robust US and ANZ market expansion, with total transaction volume surging and credit losses forecast below 1.75%. The company reconfirms FY26 guidance, underpinned by AI-driven underwriting and new subscription offerings.

Amcor posted a 77% jump in Q3 net sales fueled by the Berry acquisition, delivering synergy gains above expectations and updating fiscal 2026 guidance amid geopolitical headwinds.

Anteris Technologies has treated the first US patients in its global PARADIGM trial, marking a key milestone in testing its DurAVR transcatheter heart valve against established devices.

Nova Eye Medical has smashed its US sales record in April 2026, prompting an upgrade to its FY26 sales guidance and marking a milestone with positive operational EBITDA.

Beamtree Holdings has landed a $2 million contract with Saudi Arabia’s Fakeeh Care Group, while revising down its FY26 ARR growth guidance and outlining cost-cutting measures as part of an ongoing strategic review.

Sigma Healthcare reports robust growth in Chemist Warehouse sales across Australia and internationally, announces a joint venture to enter the UK market, and secures a major distribution centre lease in New Zealand to support its expanding network.

ImpediMed has secured A$15.2 million through a two-tranche placement and share purchase plan, alongside A$5 million in cost reductions, aiming for operating cashflow breakeven by H2 FY28.

Imricor Medical Systems has secured A$60 million through a placement to fund its US commercial rollout, regulatory approvals, and clinical programs, boosting its cash reserves to nearly A$103 million.